Aomuke Pharmaceutical

Hangzhou Aomuke Pharmaceutical Joint-stock Co., Ltd. was founded by Dr. Qi Youmao, a returnee from overseas. It is a *high-tech enterprise centered on the research and development of new drugs with independent intellectual property rights. The company is committed to the research, development and industrialization of national Class I new drugs in the field of major diseases that seriously affect people's health. Founded in October 2000, the company currently owns more than 20 invention patents, 3 international invention patents, and has developed 5 Class 1.1 new drugs, and has completed CFDA registration for more than 100 projects. The company has established an enterprise R&D center and an academician expert workstation, including screening platforms for chemical drugs, natural drugs, pharmaceutical preparations, etc., and also has a complete innovative drug research and technology development system. It has basically completed the layout of the entire value chain covering drug research, drug development, manufacturing, and marketing. The company has successively been approved for the national "Twelfth Five-Year" "Major New Drug Creation" project and the "Innovation Fund" project of the Ministry of Science and Technology for technology-based small and medium-sized enterprises, and has also received support from the "Zhejiang Provincial Major Science and Technology Special Project". Aomikesong® (Sugammadex Sodium Injection) was approved for marketing by China's National Medical Products Administration in June 2026, and is currently the world's * patent-protected drug in the field of neuromuscular blockade reversal. Sugammadex sodium has completed a bridging study in the Australian population and has held an EOP II meeting with the U.S. FDA, and will launch overseas clinical trials in 2026. R&D progress of other pipeline products: Aom0319, Aom0315 and Aom0304 have all completed Phase I clinical trials in Australia and started the next phase of clinical research. The company has new drug industrialization bases equipped with APIs, solid preparations, injections, etc., and has established strategic partnerships with domestic and foreign research institutions and pharmaceutical companies; with the mission of developing "the medicine of tomorrow, benefiting life", the company continuously surpasses itself, is brave in innovation and progress, and is determined to strive for the cause of human health!